Soft tissue sarcoma: biology and therapeutic correlates by Hannay, Jonathan A.F.
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Hannay, Jonathan A. F. (2015) Soft tissue sarcoma: biology and 
therapeutic correlates. PhD thesis. 
 
http://theses.gla.ac.uk/6988/  
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
Soft Tissue Sarcoma: Biology 
and Therapeutic Correlates.
Jonathan AF Hannay
BSc (Hons), MBChB, FRCSGlasg (Gen. Surg)
A thesis submitted in December 2014 
to the University of Glasgow 
for the degree of Doctor of Philosophy 
by published work   1
incorporating publications arising from research carried out in 
the department of Surgical Oncology at the University of 
Texas MD Anderson Cancer Centre, Houston, Texas, USA. 
  © Jonathan AF Hannay 2014, except for the published papers contained here-in where 1
copyright is retained by the original holders as indicated.  Copies of this thesis may be 
reproduced by photocopying except for those sections composed of the previously 
published research papers where permission for copying should be sought from the 
original holders.  
  .1
Summary
Soft tissue sarcomas (STS) comprise a heterogenenous group of greater than 50 
malignancies of putative mesenchymal cell origin and as such they may arise in diverse 
tissue types in various anatomical locations throughout the whole body.  Collectively they 
account for approximately 1% of all human malignancies yet have a spectrum of 
aggressive behaviours amongst their subtypes.  They thus pose a particular challenge to 
manage and remain an under investigated group of cancers with no generally applicable 
new therapies in the past 40 years and an overall 5-year survival rate that remains 
stagnant at around 50%.  
From September 2000 to July 2006 I undertook a full time post-doctoral level research 
fellowship at the MD Anderson Cancer Center, Houston, Texas, USA in the department of 
Surgical Oncology to investigate the biology of soft tissue sarcoma and test novel anti-
sarcoma adenovirus-based therapy in the preclinical nude rat model of isolated limb 
perfusion against human sarcoma xenografts.  This work, in collaboration with colleagues 
as indicated herein, led to a number of publications in the scientific literature furthering our 
understanding of the malignant phenotype of sarcoma and reported preclinical studies 
with wild-type p53, in a replication deficient adenovirus vector, and oncolytic adenoviruses 
administered by isolated limb perfusion.  Additional collaborative and pioneering 
preclinical studies reported the molecular imaging of sarcoma response to systemically 
delivered therapeutic phage RGD-4c AAVP.  
Doxorubicin chemotherapy is the single most active broadly applicable anti-sarcoma 
chemotherapeutic yet only has an approximate 30% overall response rate with additional 
breakthrough tumour progression and recurrence after initial chemo-responsiveness 
further problematic features in STS management.  Doxorubicin is a substrate for the multi-
drug resistance (mdr) gene product p-glycoprotein drug efflux pump and exerts its main 
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mode of action by induction of DNA double-strand breaks during the S-phase of the cell 
cycle.  Two papers in my thesis characterise different aspects of chemoresistance in 
sarcoma.  The first shows that wild-type p53 suppresses Protein Kinase Calpha (PKCα) 
phosphorylation (and activation) of p-glycoprotein by transcriptional repression of PKCα 
through a Sp-1 transcription factor binding site in its -244/-234 promoter region.  The 
second paper demonstrates that Rad51 (a central mediator of homologous recombination 
repair of double strand breaks) has elevated levels in sarcoma and particularly in the S-
G2 phase of the cell cycle.  Suppression of Rad51 with small interfering RNA in sarcoma 
cell culture led to doxorubicin chemosensitisation.  Reintroduction of wild-type p53 into 
STS cell lines resulted in decreased Rad51 protein and mRNA expression via 
transcriptional repression of the Rad51 promoter through increased AP-2 binding.   
In light of poor response rates to chemotherapy, escape from local control portends a poor 
prognosis for patients with sarcoma.  Two papers in my thesis characterise aspects of 
sarcoma angiogenesis, invasion and metastasis.  Human sarcoma samples were found to 
have high levels of matrix metalloproteinase-9 (MMP-9) with expression levels that 
correlated with p53 mutational status.  MMP-9 is known to degrade extracellular collagen, 
contribute to the control of the angiogenic switch necessary in primary tumour progression 
and facilitate invasion and metastasis.  Reconstitution of wild-type p53 function led to 
decreased levels of MMP-9 protein and mRNA as well as zymography-assessed MMP-9 
proteolytic activity and decreased tumour cell invasiveness.  Reintroduction of wild-type 
p53 into human sarcoma xenografts in-vivo decreased tumour growth and MMP-9 protein 
expression.  Wild-type p53 was found to suppress mmp-9 transcription via decreased 
binding of NF-κB to its -607/-595 mmp-9 promoter element.  Studies on the role of the 
VEGF165 in sarcoma found that sarcoma cells stably transfected with VEGF165 formed 
more aggressive xenografted tumours with increased vascularity, growth rate, metastasis, 
and resistance to chemotherapy.  Use of the anti-VEGFR2 antibody DC101 enhanced 
doxorubicin sensitivity at sub-conventional dosing, inhibited tumour growth, decreased 
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development of metastases, and reduced tumour micro-vessel density while increasing 
the vessel maturation index.  These effects were explained primarily through effects on 
endothelial cells (e.c.s), rather than the tumour cells per se, where DC101 induced e.c. 
sensitivity to doxorubicin and suppressed e.c. production of MMPs.  
The p53 tumour suppressor pathway is the most frequently mutated pathway in sarcoma.  
Recapitulation of wild-type p53 function in sarcoma exerts a number of anti-cancer 
outcomes such as growth arrest, resensitisation to chemotherapy, suppression of 
invasion, and attenuation of angiogenesis.  Using a modified nude rat-human sarcoma 
xenograft model for isolated limb perfusion (ILP) delivery of wild-type p53 in a replication 
deficient adenovirus vector I showed that functionally competent wild-type p53 could be 
delivered to and detected in human leiomyosarcoma xenografts confirming preclinical 
feasibility - although not efficacious due to low transgene expression.  Viral fibre 
modification to express the RGD tripeptide motif led to greater viral uptake by sarcoma 
cells in vitro (transductional targeting) and changing the transgene promoter to a response 
element active in cells with active telomerase expression restricted the transgene 
expression to the tumour intracellular environment (transcriptional targeting).  Delivery of 
the fibre-modified, selectively replication proficient oncolytic adenovirus Ad.hTC.GFP/
E1a.RGD by ILP demonstrated a more robust, and tumour-restricted, transgene 
expression with evidence of anti-sarcoma effect confirmed microscopically.  Collaborative 
studies using the fibre modified phage RGD-4C AAVP confirmed that systemic delivery 
specifically, efficiently, and repeatedly targets human sarcoma xenografts, binds to αv 
integrins in tumours, and demonstrates a durable, though heterogeneous, transgene 
expression of 1-4 weeks.  Incorporation of the Herpes Simplex Virus thymidine kinase 
(HSVtk) transgene into RGD-4C AAVP permitted CT-PET spatial and temporal molecular 
imaging in vivo of transgene expression and allowed quantification of tumour metabolic 
activity both before and after interval administration of a systemic cytotoxic with 
predictable and measurable response to treatment before becoming apparent clinically.  
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These papers further the medical and scientific community’s understanding of the biology 
of soft tissue sarcoma and report preclinical studies with novel and promising anti-
sarcoma therapeutics.  
  .5
Contents
Page
Title page  ………………………………………………………………………………… 1
Summary  ………………………………………………………………………………… 2
Contents  …………………………………………………………………………………. 6
Acknowledgements  …………………………………………………………………….. 8
Declaration  ………………………………………………………………………………. 10
Abbreviations  ……………………………………………………………………………. 11
Explanatory essay  ………………………………………………………………………. 12
Soft Tissue Sarcoma: biology of chemoresistance
Paper 1  
“Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is 
involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation.” 
Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE.
J Biol Chem. 2005 Feb 11;280(6):4825-33.  PMID: 15563462  …………………….. 31
Paper 2  
“Rad51 overexpression contributes to chemoresistance in human soft tissue 
sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.” 
Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, 
Pollock RE, Lev D. 
Mol Cancer Ther. 2007 May;6(5):1650-60.  PMID: 17513613  …………………….. 41
Soft Tissue Sarcoma: biology of angiogenesis, invasion, and metastasis
Paper 3  
“Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 
promoter activation: implications for soft tissue sarcoma growth and metastasis.” 
Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, 
Pollock RE, Lev D. 
Mol Cancer Res. 2006 Nov;4(11):803-10.  PMID: 17077165  ……………………… 53
Paper 4  
“Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: 
implications for tumor growth, metastasis, and chemoresistance.” 
  .6
Zhang L1, Hannay JA1, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock 
RE, Lev D. 
Cancer Res. 2006 Sep 1;66(17):8770-8.  PMID: 16951193  (1 co-first authorship). 62
Soft Tissue Sarcoma: preclinical studies with therapeutic correlates
Paper 5  
“Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-
modified oncolytic adenoviruses to extremity sarcoma.” 
Hannay J, Davis JJ, Yu D, Liu J, Fang B, Pollock RE, Lev D. 
Gene Ther. 2007 Apr;14(8):671-81.  PMID: 17287860  …………………………….. 72
Paper 6  
“A preclinical model for predicting drug response in soft-tissue sarcoma with 
targeted AAVP molecular imaging.” 
Hajitou A, Lev DC, Hannay JA, Korchin B, Staquicini FI, Soghomonyan S, 
Alauddin MM, Benjamin RS, Pollock RE, Gelovani JG, Pasqualini R, Arap W. 
Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4471-6.  PMID: 18337507  …….. 84
References  ………………………………………………………………………………. 91
  .7
Acknowledgements
I would like to acknowledge the support, advice, and encouragement from the following 
people:  
My parents Walter & Gillian Hannay for their patience, loving support and righteous 
example of wisely lived lives.  
Dr Nora Janjan (former Professor of Radiation Oncology and Symptom Research at The 
University of Texas M.D. Anderson Cancer Center) and Prof. David George (former 
Professor of Surgery, University of Glasgow) for encouragement to pursue a period of 
research apart from clinical commitments to properly learn the discipline of laboratory 
based research and make a meaningful contribution to cancer research.  
Dr Raphael E Pollock (former Professor of Surgical Oncology, Chairman of the 
Department of Surgical Oncology, and Chief of the Division of Surgery, University of Texas 
M.D. Anderson Cancer Center) for appointing me as his research fellow, funding, and 
patientience in guiding & constraining my involvement in the projects that I undertook.  
Dr Dihua Yu (Professor of Molecular and Cellular Oncology, University of Texas M.D. 
Anderson Cancer Center) for clear and experienced scientific advice.  
Dr Dina C Lev (Associate Professor of Cancer Biology, University of Texas M.D. Anderson 
Cancer Center) for encouragement and bracing scientific discussion.  
The many members of the Pollock, Yu, and Lev labs for daily helpful advice, 
encouragement and long lasting friendship.  Particular thanks are due to Drs Maocheng 
Zhan, Juehui Liu, and Lianglin Zhang for close collaborative and mutual help as well as 
their ready agreement to include their papers that I contributed to in this thesis.
Drs Renata Pasqualini and Wadhi Arap (Professors of Genitourinary Medical Oncology, 
University of Texas M.D. Anderson Cancer Center) and members of their lab for scientific 
discussion and collaborative work on bacteriophage based studies in sarcoma.  Particular 
thanks is due to Dr Amin Hajitou (now at Imperial College, London) for close collaborative 
help and permission to include his paper that I contributed to in this thesis.
  .8
Drs Frank Marini and Dr Bingliang Fang, both of University of Texas M.D. Anderson 
Cancer Center, for advice, help, and provision of test reagents in the investigation of anti-
sarcoma adenovirus therapy.  
Dr Peggy Tinkey and staff in the Veterinary Medicine Dept. of University of Texas M.D. 
Anderson Cancer Center for help, advice, and assistance in humane management of 
experiments involving animals.  Particular thanks to Gary Klaassen for expert assistance 
with refinement of the isolated limb perfusion model.  
Prof. Patrick J O’Dwyer (Professor of Surgery, University of Glasgow) and Mr Andrew J 
Hayes (Dept. Academic Surgery, the Royal Marsden Hospital, London) for helpful and 
stimulating advice on thesis preparation and discussions on the evolving management of 
sarcomas clinically.
Finally, special thanks to the Leonardo family, USA for their love, warmth, and generosity 
in providing me more than a home-from-home while I undertook my fellowship in the USA.  
  .9
Declaration
I hereby declare that, where indicated and itemised in the accompanying explanatory 
essay, I personally conceived and undertook the research projects, performed the 
experimentation, interpreted the results, drafted, edited, and submitted the accompanying 
peer-reviewed published papers arising from my Surgical Oncology post-doctoral 
research fellowship at the University of Texas M.D. Anderson Cancer Center, Houston 
Texas, USA during the period of September 2000 through June 2006.  
____________________
Jonathan AF Hannay.
  .10
Abbreviations
AAVP adeno-associated virus phage
AP-2 activator protein 2
CAR cocsackie-adenovirus receptor 
DNA deoxyribonucleic acid
e.c. endothelial cells
HSVtk Herpes Simplex Virus thymidine kinase
GIST gastro-intestinal stromal tumour
ILP isolated limb perfusion
mdr-1 multi-drug resistance gene 1
MMP-2 matrix metallo-proteinase 2
MMP-9 matrix metallo-proteinase 9
mRNA messenger ribonucleic acid
NER nucleotide excision repair
NF-κB nuclear factor kappa B
NSAIDs non-steroidal anti-inflammatory drugs
p53 tumour suppressor p53 gene
p53 tumour suppressor p53 protein
PDGFRα platelet derived growth factor receptor alpha 
PDGFRβ platelet derived growth factor receptor beta 
PKCα protein kinase C alpha
rad51 rad51 gene
Rad51 Rad51 protein
RGD arginine-glycine-aspartic acid tripeptide
siRNA short inhibitory ribonucleic acid
SP-1 specificity protein 1
STS soft tissue sarcoma
VEGF vascular endothelial growth factor
VEGFR1 vascular endothelial growth factor receptor 1 
VEGFR2 vascular endothelial growth factor receptor 2 
VEGFR3 vascular endothelial growth factor receptor 3 
WHO World Health Organisation
  .11
Explanatory Essay
Introduction  
Soft tissue sarcomas (STS) comprise a heterogenenous group of greater than 50 
malignancies of putative mesenchymal cell origin.  As such they may arise in diverse 
tissue types in various anatomical locations throughout the whole body including muscle, 
fat, peripheral nerve components, and fibrous tissue types, etc.  Considering that 
mesenchymally derived tissue accounts for over 75% of the mass of an adult human it is 
surprising that STS is not encountered more frequently than the 1% of all malignancies it, 
as a group, accounts for.  None-the-less, in 2012 it was anticipated that there would be 
over 11,000 new cases of STS in the USA[1] and over 2,300 in England and Wales[2, 3].  
The World Health Organization (WHO) recognizes that diagnosis and management of 
these cancers pose a particular challenge for clinicians due to the following compounding 
layers of complexity[4]:  
1. The relative rarity of STS: the incidence of STS as a group is approximately 30/
million accounting, as mentioned above, for around 1% of adult human 
malignancies.  
2. The heterogeneity of subtypes: over 50 different sub-types of STS are 
categorized in the World Health Organization Classification of Tumours: 
Pathology and Genetics of Tumours of Soft Tissue and Bone.  
3. The diverse lineages or host / parental tissue types that STS arises in and the 
resultant diverse histopathologic characteristics.
4. The wide range of behaviours from fairly indolent to highly invasive and 
aggressive.  
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5. The age range of affected patients: STS accounts for 15% of paediatric 
malignancies and the overall incidence rises with each decade of life to a peak 
around 65years of age.  
6. The incidence of benign counterparts is around 100-to-1.  
Although these tumours are by nature challenging, a thorough appreciation of STS biology 
and their management is still necessary to avoid compromised outcome if the initial 
management of patients with these tumours is sub-optimal[5].  Tragically, though, in spite 
of multimodal treatment in ‘centres of excellence’ and despite the relative successes in 
some STS subtypes - such as imatinib for the treatment of gastro-intestinal stromal 
tumours (GISTs) - the 5-year survival rate for patients with STS remains stagnant at 
around 50%.  
Perhaps because of their relative rarity and complexity, STS remains an under-
investigated tumour group in recent decades in contrast to the milestones of generally 
applicable biologic insights gained previously from basic science research of sarcomas - 
dating from Peyton Rous’ seminal work on the transmission of avian spindle cell sarcomas 
in Plymouth Rock hens, published in 1911[6].  No doubt related to this paucity of 
investigation, there have been no broadly applicable new therapies for STS in the past 40 
years beyond the use of doxorubicin and ifosphamide based chemotherapy regimens.  
This baneful state compels investigation into soft tissue sarcoma biology with the hopeful 
view of rational development of therapeutic correlates - the purpose of this thesis by 
published work.  
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Fellowship and research background
In September 2000 I undertook a full-time, laboratory-based, Surgical Oncology Research 
Fellowship at the University of Texas’ MD Anderson Cancer Center, Houston, Texas, USA 
under the direction of Dr Raphael Pollock, Chief of Surgery (now at the University of 
Ohio).  Dr Pollock’s laboratory was, and is, one of the few laboratories in the world 
focusing on the research and treatment of soft tissue sarcoma and was run with co-
directorship from Dr Dihua Yu (Professor of Molecular & Cellular Oncology, University of 
Texas) during my first 4 years and Dr Dina Lev (Assistant Professor of Cancer Biology, 
University of Texas) during my later 2 years in the lab.  My recruitment to this post-doctoral 
research fellowship drew from my previous experience in molecular biology research and 
surgical training allowing me to contribute to active research projects in the lab while 
refining and utilising the group’s animal model for delivery of novel anti-sarcoma 
therapeutics.  
At the commencement of my research fellowship the main strands of research within the 
group were the role of the tumour suppressor p53 in the development of the malignant 
hallmarks of sarcoma, wild-type p53 reconstitution as a potential therapeutic following 
adenoviral delivery, and angiogenesis induction by sarcoma.  Collaborative work within 
our group, and within the institution, led to the publication of a number of co- and first-
author papers of which 6 have been selected for submission in this thesis by published 
work entitled “Soft Tissue Sarcoma: Biology and Therapeutic Correlates”.  
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Publications and contribution.  
The publications submitted in this thesis are:  
1. “Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified 
oncolytic adenoviruses to extremity sarcoma.” 
Hannay J, Davis JJ, Yu D, Liu J, Fang B, Pollock RE, Lev D. 
Gene Ther. 2007 Apr;14(8):671-81.  
PMID: 17287860  
My contribution to this paper was: 
• hypothesis generation and testing, 
• experiment design: all figures, 
• experiment execution
• Figure 1: all panels, 
• Figure 2: all panels, 
• Figure 3: all panels, 
• Figure 5, 
• data interpretation, 
• manuscript writing, editing, submission, and reply to reviewer’s comments.  
2. “Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma 
cells: a role for p53/activator protein 2 transcriptional regulation.” 
Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, 
Pollock RE, Lev D. 
Mol Cancer Ther. 2007 May;6(5):1650-60.  
PMID: 17513613  
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My contribution to this paper was: 
• hypothesis generation and testing, 
• experiment design: all figures, 
• experiment execution
• Figure 1: all panels, 
• Figure 2: all panels, 
• Figure 3: all panels, 
• Figure 4: all panels, 
• Figure 5: D - preparation of viruses and virally infected cells, 
• data interpretation, 
• manuscript writing, editing, proof reading, and submission.  
3. “Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: 
implications for tumor growth, metastasis, and chemoresistance.” 
Zhang L1, Hannay JA1, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, 
Pollock RE, Lev D. 
Cancer Res. 2006 Sep 1;66(17):8770-8.  
PMID: 16951193  
(1 co-first authorship)
My contribution to this paper was: 
• experiment design: figures 2 and 6, 
• experiment execution (shared): figures 2 and 5: all panels, 
• data interpretation, 
• manuscript preparation, editing, submission, reply to reviewer’s comments, rewriting, 
and resubmission.  
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4. “A preclinical model for predicting drug response in soft-tissue sarcoma with targeted 
AAVP molecular imaging.” 
Hajitou A, Lev DC, Hannay JA, Korchin B, Staquicini FI, Soghomonyan S, Alauddin 
MM, Benjamin RS, Pollock RE, Gelovani JG, Pasqualini R, Arap W. 
Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4471-6.  
PMID: 18337507  
My contribution to this paper was: 
• hypothesis generation and testing, 
• experiment execution (shared)
• Figure 2: all panels, 
• Figure 3: all panels, 
• Figure 4: all panels, 
• data interpretation, 
• manuscript proof-reading and editing.  
5. “Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is 
involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation.” 
Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE.
J Biol Chem. 2005 Feb 11;280(6):4825-33.  
PMID: 15563462  
My contribution to this paper was: 
• independently repeat and confirm reproducibility of the western blot analyses (figure 1), 
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• amplify, purify, and titrate the viruses used in figure 4: A-C, and provide experimental 
assistance, 
• data interpretation, 
• manuscript proof-reading and editing.  
6. “Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 
promoter activation: implications for soft tissue sarcoma growth and metastasis.” 
Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, 
Pollock RE, Lev D. 
Mol Cancer Res. 2006 Nov;4(11):803-10.  
PMID: 17077165  
My contribution to this paper was: 
• assist in sarcoma tissue sample selection, processing, and data retrieval - figure 1 and 
table 1, 
• amplify, purify, and titrate the viruses used in figure 5 A, and provide experimental 
assistance,
• data interpretation, 
• manuscript preparation, editing, and proof-reading.  
Rather than submit the papers in a strictly chronological sequence according to their 
appearance in the literature, or according to degree of contribution, I present the papers 
as follows in thematic pairs.  
Paper 1: “Transcriptional repression of protein kinase C-alpha via Sp1 by wild type p53 is 
involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation.” and paper 
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2: “Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma 
cells: a role for p53/activator protein 2 transcriptional regulation.” both relate to the 
problem of soft tissue sarcoma’s resistance to chemotherapy.  These papers describe the 
characterisation of two separate molecular mechanisms of chemoresistance exhibited by 
soft tissue sarcoma in the context of p53 mutation status - the tumour suppressor most 
frequently abrogated in human cancer and of particular importance in soft tissue sarcoma.  
One of the principal mechanisms of chemoresistance development by cancer cells is the 
up-regulation of chemotherapy drug efflux pumps.  The mdr-1 gene product p-glycoprotein 
drug efflux pump is up-regulated in sarcoma cells and extrudes doxorubicin - the mainstay 
anti-sarcoma chemotherapeutic - as well as many other drugs.  Wild-type p53 activation 
was already known to transcriptionally repress mdr-1 gene transcription however, paper 1 
demonstrated another new layer of control of the doxorubicin efflux pump in sarcoma in 
that wild-type p53 activation transcriptionally represses the activating kinase of p-
glycoprotein (PKCa) through inhibition of the SP-1 transcription factor binding on the 
PKCa promoter.  In sarcoma, therefore, loss of wild-type p53 may lead to 
chemoresistance by increased drug extrusion from tumour cells through two levels of loss 
of control: at the transcriptional level of the mdr-1 gene, and at the functional level of the 
p-glycoprotein pump.  
Paper 2 characterises a mechanism of chemoresistance in sarcoma that relates to the 
functional mechanism of the mainstay anti-sarcoma agents: doxorubicin chemotherapy 
and ionising radiation.  Both of these agents have as their principle mode of action the 
induction of double-strand DNA breaks.  Cells are critically sensitive to this form of DNA 
damage and, in cycling cells, repair such breaks via homologous recombination.  The 
central mediator of homologous recombination is the protein Rad51.  Paper 2 
demonstrates that Rad51 is over-expressed in soft tissue sarcoma, particularly in cells 
harbouring p53 mutation, and accumulates in the G2 phase of the cell cycle where 
doxorubicin causes cycling sarcoma cells to arrest.  Suppression of Rad51 by siRNA 
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rendered sarcoma cells with elevated Rad51 levels to become more chemosensitive at 
clinically meaningful concentrations of chemotherapeutic.  Additionally, reconstitution of 
wild-type p53 function led to suppression of Rad51 levels via transcriptional repression 
mediated through AP2 binding to the rad51 promoter.  This paper was the first in the 
literature to investigate and characterise the role of Rad51 in sarcoma chemoresistance 
yielding, what should be, a therapeutically relevant insight.  
Paper 3: “Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 
promoter activation: implications for soft tissue sarcoma growth and metastasis.” and 
paper 4: “Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: 
implications for tumor growth, metastasis, and chemoresistance.” both relate to soft tissue 
sarcoma growth, invasion, and metastasis.  Paper 3 was the first report in the literature 
examining MMP-9 in sarcoma and shows that MMP-9 is over-expressed in sarcoma and 
that expression levels correlate with both metastasis and p53 mutational status.  
Reconstitution of wild-type p53 function led to down regulation of functional MMP-9 and 
suppression of mmp-9 transcription via altered NF-kB binding in the mmp-9 promoter.  
Paper 4 demonstrates that over-expression of the VEGF isoform 165 in sarcoma leads to 
a more aggressive phenotype for growth, invasion, and metastasis and additionally 
confers an enhanced chemoresistant phenotype in vivo.  Combining the anti-VEGFR2 
antibody DC101 with low-dose doxorubicin as a biochemotherapy strategy led to 
attenuation of the aggressive phenotype more than with conventional schedule and 
dosing of doxorubicin.  Paper 5 provides evidence that this mechanism of suppression is 
mediated through the biochemotherapy effect on tumour endothelial cells.  
Paper 5: “Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-
modified oncolytic adenoviruses to extremity sarcoma.” and paper 6: “A preclinical model 
for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular 
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imaging.” relate to testing rationally designed biologic agents in the preclinical setting.  
Following on from the findings presented in the earlier papers that wild-type p53 
reconstitution suppresses different pathways and mechanisms pertinent to the malignant 
phenotype in sarcoma, paper 5 demonstrates that functional wild-type p53, in an 
adenoviral vector, can be successfully delivered to human soft tissue sarcoma by the 
established surgical procedure of isolated limb perfusion (ILP).  Efficacy, however, is poor 
and strategies to improve anti-sarcoma treatment with therapeutic adenoviruses led to the 
demonstration that fibre-modified, selectively replication-proficient oncolytic adenoviruses 
have greater potential as clinical therapeutics against sarcoma.  The finding, reported in 
paper 5, that fibre-modified viruses containing the arginine-glycine-aspartic acid (RGD) 
tripeptide motif have greater tropism for human soft tissue sarcoma led to the 
collaborative study, published in paper 6, examining the effect of systemically delivered 
RGD-fibre modified bacteriophage as a vector for the herpes simplex virus thymidine 
kinase (HSVtk) gene.  Uptake and expression of the exogenous HSVtk gene allows whole 
body imaging with CT-PET and the radio nucleotide (18F)-FEAU to identify regions of 
expression (and regions of metabolic activity with (18F)-FDG) prior to administration of the 
non-toxic prodrug gangcyclovir that is then converted by HSV-TK to it’s toxic metabolite.  
Subsequent CT-PET imaging may then be used to ascertain sarcoma response to therapy 
at the cellular, metabolic, and molecular levels before any change occurs (if at all) in 
tumour volume.  
As can be seen, these papers have contributed to the medical and scientific community’s 
understanding of the biological processes that are at play and perturbed in soft tissue 
sarcoma and furthermore, show-case exploratory studies with rationally designed 
preclinical anti-sarcoma therapeutics.  
These papers collectively form my thesis by published work of “Soft Tissue Sarcoma: 
Biology and Therapeutic Correlates”.   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Field Developments & Future Directions 
During my research fellowship the strands of research that I was involved with opened a 
number of avenues for development of novel therapeutics or revealed biological 
processes in soft tissue sarcoma that therapeutics in development, at the time, may have 
had applicability.  Concomitant and subsequent to my fellowship a number of other 
overlapping developments occurred in the field of sarcoma biology and related 
therapeutics which resonate with and relate to my work in this thesis.  
Advances in the Use of Hyperthermia
Hyperthermia (induction of tissue temperatures of over 39ºC) is one of the oldest 
treatments for cancer and an established component of hyperthermic isolated limb 
perfusion therapy.  Hyperthermia is recognised to act as a radio- and chemosensitiser and 
a recent review[7] of over 100 clinical trials incorporating some form of hyperthermia 
identified over 20 trials where addition of hyperthermia to standard chemo- and 
radiotherapy regimens led to significant improvement in clinical outcomes and notably in 
soft tissue sarcoma[8].  Subgroup analysis of a recently reported phase 3 trial comparing 
neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk 
soft-tissue sarcoma showed that for abdominal and retroperitoneal sarcoma (where 
surgical resection is often on vital structures), addition of hyperthermia to chemotherapy 
enhanced local control and disease-free survival for patients undergoing R0 and R1 
macroscopic disease clearance but not those with macroscopically incomplete R2 
resections[9].  While it is encouraging that evolution of technology now allows application 
of hyperthermic treatment to regions other than limbs with improved local control, overall 
survival was no different between the two groups underscoring the need for new systemic 
agents.  
  .22
Of interest, treatment of sarcoma cell lines and primary cell cultures from patients with 
transgene-expressing vaccinia virus still demonstrated T-cell activating transgene 
expression in the face of exposure to hyperthermia and ifosfamide[10] - albeit in vitro.  
High pyrexia would be expected to both attenuate viral activity inside human cells and, 
with enhanced accumulation of intracellular cytotoxic agent at hyperthermic temperatures, 
greatly interfere with transcription & translation cellular machinery.  The persistence of an 
immune-stimulatory virus-based therapy in a field that has been treated with current 
‘maximal anti-sarcoma therapy’ opens an intriguing avenue of research.  
Developments in Adenovirus-based Therapy
Pre-clinical and early clinical studies with replication deficient adenovirus delivering wild-
type p53 showed promise in the treatment of aero-and-upper-digestive tract malignancies 
leading to government licensing in 2003 for treatment of head and neck cancers in 
patients in the USA & China.  This was followed two years later with approval of 
replication-selective virus for the treatment of nasopharyngeal cancer.  However, although 
use of viruses as anticancer agents remains popular in China and other parts of Asia, 
results with adenovirus based mono-therapy or systemically delivered viruses have been 
roundly disappointing.  
A number of factors, not all purely clinical, have lead to waning enthusiasm for the use of 
recombinant viruses in anti-cancer strategies.  First, without the ringing endorsement of 
clear clinical need that can’t be recapitulated with another modality then pharmaceutical 
companies are unlikely to invest in the development of new manufacturing technologies 
for large-scale production of therapeutic viruses.  Manufacturing plants that produce 
biologically active agents are different from those involved with industrial chemistry 
producing chemicals and small molecules.  Second, and allied to the previous disincentive 
for pharmaceutical companies, are the disparate and entrenched intellectual property 
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rights associated with viral and recombinant technologies that would need to be engaged 
with and brokered before the agents could be ‘brought to market’.  Third, marketability of 
virus based therapy would need to overcome the current western cultural mindset of deep 
suspicion of recombinant-DNA being put into humans and particularly if the thought is 
prevalent that ‘Big Pharma was doing it for a profit’.  Many people if offered the choice 
between swallowing a pill or being injected with a ‘manipulated virus’ will preferentially opt 
for swallowing the pill.  
Since completing my research fellowship a number of findings have emerged 
characterising host-adenovirus factors that impinge upon adenoviral therapy in the clinic 
(for recent reviews see[11] and[12]).  Studies from the 1990s established adenoviral up-
take occurring through a two step process involving viral engagement of its fibre first with 
the cell-surface Cocsackie-Adenovirus Receptor (CAR) and then with the penton base 
interacting with cellular integrins.  Modification of peptides within the virus fibre allowed 
altered tropism of the virus for cells expressing receptors other than CAR.  However, 
systemic delivery of adenoviruses still yielded very low tumour or target tissue 
transduction.  Elucidation of the host factors leading to clearance, principally by the liver, 
of systemically delivered adenovirus made clear that systemic delivery of adenoviruses is 
unlikely to be a viable therapeutic approach.  
First, adenoviruses are ubiquitous in the environment and by the time most people reach 
adult hood they have developed neutralising antibodies to the common adenoviruses - 
notably serotype 5 and -2 which were the ‘workhorse’ viruses for adenoviral gene therapy.   
Second, the innate immune system was found to have several redundant and powerful 
mechanisms of neutralising systemically delivered adenoviruses in vivo.  Adenoviruses in 
the blood stream bind IgM, complement factors, and blood clotting factors leading to 
clearance in the liver by both hepatocytes and Küpffer cells.  The coagulation factor X, for 
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example, binds the adenovirus’ major capsid protein hexon and bridges binding to 
hepatocyte surface heparin sulphate molecules[13].  Although this seemingly main 
mechanism of clearance has been of interest in gene delivery to hepatocytes, decoration 
of adenoviruses with factor X also leads to rapid triggering of NFkB early response genes 
following detection of internalised factor X in macrophages and monocytes[14].  In 
experiments where factor X binding was abrogated, IgM and complement factors (mainly 
C1q and C4) had increased binding to adenovirus particles and increased extra-hepatic 
clearance through the reticuloendothelial system again activating a pro inflammatory 
state.  In rats the systemic intravenous injection of adenovirus vectors brought about 
shock that was due to the release of platelet activating factor from the reticuloendothelial 
system[15] which may be an anticipated consequence of systemic delivery to humans 
should liver clearance mechanisms be overcome.  Internalisation of virus particles bearing 
complement C3 has also recently been found to activate a ‘mitochondrial antiviral 
signaling’ cascade that induces pro-inflammatory cytokine secretion as well as directly 
targeting C3 tagged viruses for immediate proteosomal degradation[16].  
While these findings above currently nullify adenoviruses for systemic delivery a role may 
yet remain for their restricted regional delivery in hyperthermic isolated limb perfusion of 
locally advanced irresectable limb sarcoma.  The finding that adenoviruses have inherent 
mechanisms to circumvent the effects of a deleterious intracellular milieu was capitalised 
on in the generation of early oncolytic adenoviruses[17].  Subsequent studies of the 
biological effects of the adenoviral E1b gene product found additional roles to its p53-
binding function.  During pyrexia the nucleopore transport mechanism is closed and 
nascent mRNAs (such as heat shock protein mRNAs) are exported via a nucleopore 
independent pathway that E1b is also able to utilise to guide viral RNAs out of the 
nucleus.  Dysregulation of this export mechanism in cancer cells at 37ºC was found to 
underpin the mechanism of E1b-deleted oncolytic adenoviruses[18, 19].  This mechanism 
goes part way to explain the finding that adenovirus-delivered transgenes often have 
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robust expression in situations of hyperthermia and would further encourage consideration 
of use of adenovirus based therapy in the hyperthermic isolated limb perfusion context.  
New Systemic Therapies.  
Doxorubicin still remains the benchmark anti-sarcoma therapy for systemic treatment of 
non-GIST tumours that escape local control.  Intensified doxorubicin plus ifosfamide in 
combination demonstrated no superiority to doxorubicin alone in a recently published 
trial[20].  In this report overall survival was was 12-14 months, progression-free survival 
4-7months, and overall response to treatment 14% in the doxorubicin alone group 
compared to 26% in the combination group.  There clearly still remains a desperate need 
for new systemic therapies.  
Trabectedin 
Trabectedin (ET-743, Yondelis®) is a synthetic anticancer agent derived from the 
Caribbean marine tunicate, Ecteinascidia turbinata and now approved for clinical use in 
sarcoma in over 70 countries having received first approval for use in sarcoma in the 
European Union in 2007.  Trabectaedin has a number of modes of action.  First, it’s 
principle activity is as a guanine alkylating agent binding the minor groove of the DNA 
double helix leading to a conformational bend in DNA and inhibiting local transcription 
factor binding as well as inducing DNA double strand breaks through interference in 
transcription-coupled nucleotide excision repair (NER).  Second, trabectedin consequently 
leads to apoptosis and sensitisation to Fas-mediated cancer cell death.  Third, trabectedin 
has the unusual property of significantly altering the cancer cell environment through 
selective killing of tissue monocytes and tumour macrophages while sparing neutrophil 
and lymphocyte populations[21].  This effect both suppresses angiogenesis[22, 23] and 
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alters the tumour environment associated inflammatory state[24].  Of interest, a recent 
retrospective study assessing DNA repair gene expression patterns in advanced sarcoma 
samples from 245 patients treated with trabectedin found that active NER genes were 
associated with trabectedin sensitivity but active homologous repair pathway genes were 
negatively associated leading to the proposal of a DNA repair ‘signature’ that may predict 
response of patients with advanced sarcoma to trabectedin[25].  Neither Rad51 nor p53 
were assessed in the study.  
Trabectedin has been tested in phase I, II, and phase III trials both in combination with 
established chemotherapeutics and as mono-therapy in patients who have failed on 
standard chemotherapeutics (for a recent review see[26]).  Generally response rates are 
less than 12% with tendency to improved progression-free survival but rarely improved 
overall survival.  Response appears to be greatest when trabectedin is administered as a 
24h infusion, combined with doxorubicin, or if the sarcoma subtypes are leiomyosarcoma, 
round cell liposarcoma, or sarcomas with translocation gene products where trabectedin 
has been investigated as mono-therapy[27-29].  Currently, trabectedin has established 
itself as a new systemic therapy that appears to be at least as good as doxorubicin and 
ifosfamide in soft tissue sarcoma.  
There as yet no published studies assessing the combination effect of trabectedin with 
adenoviral gene therapy.  Since trabectedin diminishes local macrophage / monocyte 
populations and consequently still possesses an anticancer effect even in the face of 
trabectedin resistant tumour cells[21], it is intriguing to consider that this indirect effect of 
trabectedin may enhance regional anti-sarcoma adenoviral therapy and merits 
investigation.  
Pazopanib
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Pazopanib (GW786034, Votrient®) is a small molecule inhibitor of tyrosine kinases that 
was first developed against VEGFR2 but was found to have activity against related 
tyrosine kinases VEGFR1, VEGFR3, PDGFRα, PDGFRβ and c-kit.  Pazopanib was first 
approved for use against metastatic renal cell carcinoma in the USA in 2009 but has also 
been found to have statistically significant activity against metastatic soft tissue sarcoma 
while preserving a low side effect profile (reviewed in [30] and [31]).  Although a number of 
anti-angiogenic agents such as monoclonal antibodies and small molecule inhibitors have 
entered the general anticancer armamentarium, and not as first-line mono-therapy, only 
pazopnib has been regarded as an agent worth considering as standard of care in non-
adipocytic sarcoma following on from results of phase II and phase III trials.  Recently 
published analysis of pooled data from phase II and phase III studies of pazopanib in the 
European Union found that out of 344 patients with STS treated with pazopanib median 
progression free survival was 4.4. months and median overall survival 11.7 months.  
However, in approximately a third of treated patients PFS was over 6 months and OS over 
18 months with one-in-thirty patients surviving over 2 years on therapy[32].  Pazopanib’s 
superiority in sarcoma over related tyrosine kinase inhibitors may be due to it’s principle 
target being VEGFR2.  Recent data indicates that amongst the pro-angiogenic receptor 
tyrosine kinases, VEGFR2 over expression in human STS samples correlates most tightly 
with poorer survival[33].  
Innate and acquired resistance mechanisms against pazopanib have yet to be studied in 
soft tissue sarcoma.  Common mechanisms of resistance to antiangiogenesis therapy in 
other cancer types that would be of particular relevance for sarcoma include acquisition of 
a phenotype for survival in hypoxic environments, up regulation of redundant 
proangiogenic signalling pathways, recruitment of tumour associated fibroblasts & 
circulating marrow-derived cells for denser pericyte coverage of tumour neovasculature, 
up regulation of mdr genes, and p53 mutation[34].  
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mdr-1 inhibitors
Since the discovery of mdr-1 and its gene product p-glycoprotein there has been interest 
in identifying inhibitors of this drug efflux pump that is a potent effector of chemoresistance 
in tumour cells.  Many agents identified as effective inhibitors in vitro to restore 
chememosensitivity have had the drawback of being too toxic in vivo either due to too 
broad inhibitory action on other necessary efflux pumps (such as verapamil) or requiring 
infeasibly high tissue concentrations without generating toxicity (such as cyclosporin A).  
Since the completion of my fellowship further studies of mdr-1 in sarcoma have identified 
an effect of non-steroidal anti-inflammatory drugs (NSAIDs) in reversing multi drug 
resistance in uterine sarcoma cell lines[35] and also that delivery of anti-mdr-1 siRNA on 
nanoparticles can suppress chemoresistance in preclinical studies of osteosarcoma[36].  
More recently, however, newer small molecules of promise have been identified via high 
throughput screening assays that are able to reverse the chemoresistant phenotype at 
micro molar tissue concentrations[37, 38].  
MDM2-p53 interfering drugs
Mutation hot-spots in the p53 gene occur in regions altering DNA binding, folding, and 
additionally shorten the half-life of the fully folded protein at 37ºC.  The discovery that p53 
C-terminal modification, including by binding with antibiodies, can lead to reactivation of 
DNA binding by mutant p53 led to a search for p53 stabilising agents.  Identification of 
agents that stabilise p53 and ‘reactivate’ mutated p53 are attractive therapeutics since 
they would circumvent hurdles associated with gene-therapy reintroduction of functional 
wild-type p53 (reviewed in [39] and [40]).  Strategies to reactivate native p53 broadly fall 
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into two categories: those agents that bind p53 directly or those that inhibit p53’s negative 
regulator MDM2.  The most investigated of these compounds are the MDM-2 antagonists 
and in particular the nutlins and their derivatives which bind the p53 binding pocket of 
MDM2 with greater affinity than p53.  These agents have been shown to enhance 
chemosensitivity and radiosensitivity, change MDM2 folding, reverse p-glycoprotein 
mediated chemoresistance, suppress tumour associated angiogenesis and lead to 
sarcoma regression in preclinical and clinical studies (reviewed in [41]).  
Summary
Although a number of years have passed since the completion of my fellowship and the 
incorporation of this thesis arising from findings during my fellowship, soft tissue sarcoma 
remains an under investigated tumour type.  The promise of viral gene therapy from the 
late 1990s has paled and further developments with small molecule inhibitors of 
characterised biologic pathways hold out future promise for rationally designed and 
personalised treatment of patients with sarcoma.  The surgical oncologist still retains a 
central role in the holistic care of the patient with sarcoma and additionally should be an 
integrated figure in bridging the development of new therapies between the laboratory and 
bedside patient care: a role I still seek to develop.  
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